STAAR Surgical Company (STAA) is a Healthcare stock trading at $23.13 (as of 2026-09-02), with a market capitalization of $1.15B and a trailing P/E of 298.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
STAAR Surgical Company designs, develops, manufactures, markets, and sells implantable eye lenses and related delivery systems. Its product lines include implantable Collamer lenses and cataract intraocular lenses with corresponding injector systems, which it supplies to ophthalmic surgeons and other healthcare providers through direct sales and distributors.
STAAR Surgical designs and sells premium implantable contact lenses (ICLs) and cataract surgery kits to ophthalmic surgeons for refractive and cataract procedures. The Visian ICL franchise is the core product, with China driving the majority of volume and a proprietary lens-plus-delivery-system moat in premium refractive surgery.
The 63-point spread between 74% gross margin and 11% operating margin is the entire story: each ICL earns a premium price, but building out the global commercial franchise (sales force, distributors, plant capacity, post-merger integration) still consumes most of that gross before it reaches the bottom line.
| China | $0.1B |
| Ex-China | $0.0B |
Business quality (Mixed): A genuinely high-margin product franchise (74% gross) held back by a thin operating margin (11%) that reflects heavy investment in distribution, manufacturing footprint, and innovation. The 111% revenue recovery is real but off a disrupted base, and the valuation leaves no room for a missed quarter.
Valuation: At 299× earnings, STAA trades 815% above the Medical Equipment average (33×).
| Price | $23.13 |
| Market Cap | $1.15B |
| P/E Ratio | 298.3 |
| EV / EBITDA | 45.2 |
| Price / Book | 3.13 |
| Price / Sales | 3.37 |
| FCF Yield | -3.5% |
| Revenue (TTM) | $239.44M |
| Net Margin | -33.6% |
| Revenue Growth (YoY) | 111.0% |
| EPS Growth (YoY) | -147.1% |
| FCF Growth (YoY) | -166.1% |
| Altman Z-Score | 6.44 (safe) |
| Stock P/E | 298.3 |
| Sector P/E (Healthcare) | 21.6 |
| Industry P/E (Medical Equipment) | 29.8 |
| vs Sector | 1281.3% |
| vs Industry | 902.6% |
| Top Institutional Holder | BROADWOOD CAPITAL INC ($301.52M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Medical Equipment |
| CEO | Warren Foust |
| Employees | 1,157 |
| Country | US |
| IPO Date | 1992-02-24 |
Data as of 2026-09-02.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.